Key Highlights
- Anpario PLC (LSE:ANP) shares gained 6.12% on 1 October 2026, outperforming a falling FTSE 100.
- First-half 2026 Revenue rose 7% to £24.3 million, with adjusted EBITDA up 22% to £5.0 million.
- Dilution-adjusted Earnings Per Share jumped 30% to 20.77 pence.
- The Interim Dividend was raised 6% to 3.8 pence, extending a near 20-year record of dividend growth.
- Anpario completed a £3 million share buyback and held £11.0 million of cash at the half-year end.
Why Anpario Is in Focus Today
Anpario PLC (LSE:ANP), the independent manufacturer of natural animal feed additives for health, nutrition and biosecurity, rose 6.12% on 1 October 2026. The move came on a day when the FTSE 100 fell more than 1% as UK gilt yields climbed, a backdrop that tends to favour profitable, cash-rich and dividend-paying small caps with defensive end markets.
There was no fresh announcement from the company on the day. Instead, the rally looks like continued investor support following its interim results on 9 September, after the shares had closed at around 490 pence on 30 September.
Profit Growth Outpacing Sales
The headline from Anpario's first half was operating leverage. Revenue grew 7% to £24.3 million, in line with the company's long-term target of high single-digit growth. But profitability grew much faster. Adjusted EBITDA rose 22% to £5.0 million, operating profit increased 12% to £3.7 million and profit before tax rose 11% to £3.8 million. Dilution-adjusted earnings per share climbed 30% to 20.77 pence, helped by share Buybacks reducing the share count.
Gross Margin held at 50.4% despite headwinds from logistics and energy costs. Administrative costs rose only 2%, and management said that excluding non-recurring fees, they actually fell by about 3%.
Premium Brands Driving the Mix
A key positive for investors was the performance of Anpario's premium and core product brands, which make up about 80% of sales and grew 17%. The group's portfolio includes well-known names such as Orego-Stim, a natural oregano-based gut health product, along with acid-based eubiotics, pellet binders and biosecurity products. Higher-value branded products tend to support margins and pricing power.
Regional Picture
Performance by region was mixed but encouraging overall. The IMEA region, covering the Middle East, Africa and India, was the standout with sales up 56%. The Americas grew 7%. Europe was broadly flat, while Asia declined 9% due to weaker sales of toxin binders. Management noted that remaining toxin binder sales in Asia are now only about 3% of the total, limiting further downside from that product line.
Shareholder Returns Remain a Key Attraction
Anpario raised its interim dividend by 6% to 3.8 pence per share, continuing a dividend growth record stretching back nearly two decades. It also completed its share buyback programme, returning £2.1 million in the first half and £3 million overall.
The Balance Sheet remains strong, with £11.0 million of period-end cash, Operating Cash Flow before Working Capital of £4.5 million, low Capital Expenditure of around £0.4 million and net Assets of £42.1 million. That gives the company flexibility to keep rewarding shareholders and pursue acquisitions.
Building on a Record 2025
The first-half numbers follow a record 2025, when revenue rose 24% and profit before tax jumped 54%, beating market expectations. Part of that step-change came from the Acquisition of Bio-Vet in the US in 2024. Investors have been watching closely to see whether last year's improvement was sustainable, and the latest results suggest profitability gains are holding even as revenue growth moderates.
Risks and Watch Points
Management acknowledged that first-half revenue growth was softer than in some prior periods, and some analysts have flagged a more cautious sales outlook. Weather patterns such as El Niño, livestock disease cycles, slower changes to European distribution and competitive pressure in Asian toxin binders are all factors that could influence the second half.
What Comes Next
Investors in Anpario PLC (LSE:ANP) will look for second-half trading consistent with full-year expectations, further growth from premium brands and any update on acquisitions. With a net cash balance sheet, a rising dividend and improving margins, Anpario continues to attract interest as a defensive growth play in the UK small-cap space.






Please wait processing your request...